Enantioselective analysis of lansoprazole in rat plasma by LC-MS/MS: Application to a stereoselective pharmacokinetic study.

A rapid, sensitive and enantioselective method was developed and fully validated for the separation and determination of lansoprazole enantiomers in rat plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The analytes and the internal standard (esomeprazole) were both extracted from plasma samples by liquid-liquid extraction with diethyl ether-dichloromethane (70:30; v/v). Satisfactory resolution (Rs  = 2.0) was achieved within 7.3 min on a Chiralpak ID column (250 × 4.6 mm, 5 μm) employing acetonitrile-water (60:40, v/v) as the mobile phase at a flow rate of 0.6 mL/min. The acquisition of mass spectrometric data was performed in the multiple reaction monitoring mode coupled with a positive electrospray ionization source. A comprehensive validation of this method was rigorously conducted over the concentration range of 1.00-500.0 ng/mL for both enantiomers. All of the validation data demonstrated that the desirable linearity, sensitivity, accuracy, precision, recovery and stability were attained from the proposed approach. The established method was successfully applied to a stereoselective pharmacokinetic study of lansoprazole enantiomers in rat plasma after oral administration of 3 mg/kg racemic lansoprazole or dexlansoprazole. No chiral inversion was observed during the experimental procedure.

[1]  Yong-Qing Wang,et al.  Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors. , 2016, Current drug metabolism.

[2]  S. Tan,et al.  Chiral liquid chromatography-mass spectrometry (LC-MS/MS) method development for the detection of salbutamol in urine samples. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  Jian Wang,et al.  Determination of lansoprazole enantiomers in dog plasma by column-switching liquid chromatography with tandem mass spectrometry and its application to a preclinical pharmacokinetic study. , 2015, Journal of separation science.

[4]  D. Svinarov,et al.  Critical development by design of a rugged HPLC-MS/MS method for direct determination of ibuprofen enantiomers in human plasma. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  Z. Hong,et al.  Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. , 2015, Journal of pharmaceutical and biomedical analysis.

[6]  Wei Li,et al.  Determination of a deuterohemin-peptide conjugate in rat plasma by liquid chromatography-tandem mass spectrometry and application to a preclinical pharmacokinetic study. , 2014, Journal of pharmaceutical and biomedical analysis.

[7]  D. Johnson,et al.  Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium) , 2014, Expert opinion on pharmacotherapy.

[8]  C. Nakamura,et al.  Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes , 2001, European Journal of Clinical Pharmacology.

[9]  Xiaoyan Chen,et al.  Enantioselective determination of ornidazole in human plasma by liquid chromatography-tandem mass spectrometry on a Chiral-AGP column. , 2013, Journal of pharmaceutical and biomedical analysis.

[10]  Kishore Kumar Hotha,et al.  Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study. , 2012, Biomedical chromatography : BMC.

[11]  S. Nudurupati,et al.  Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg , 2011, Clinical and experimental gastroenterology.

[12]  R. Fass,et al.  Dexlansoprazole MR – A review , 2011, Annals of medicine.

[13]  P. Kole,et al.  Recent advances in sample preparation techniques for effective bioanalytical methods. , 2011, Biomedical chromatography : BMC.

[14]  Lili Lin,et al.  A novel fluorescent enantioselective discrimination of lansoprazole based on a chiral N,N′-dioxide–Sc(III) complex , 2010 .

[15]  J. Remon,et al.  A bio-analytical hydrophilic interaction LC-MS/MS method for the simultaneous quantification of omeprazole and lansoprazole in human plasma in support of a pharmacokinetic omeprazole study in children. , 2010, Journal of separation science.

[16]  Q. Cass,et al.  Two-dimensional chromatography method applied to the enantiomeric determination of lansoprazole in human plasma by direct sample injection. , 2010, Chirality.

[17]  R. Cirilli,et al.  Development and validation of an enantioselective and chemoselective HPLC method using a Chiralpak IA column to simultaneously quantify (R)-(+)- and (S)-(-)-lansoprazole enantiomers and related impurities. , 2009, Journal of pharmaceutical and biomedical analysis.

[18]  A. Wen,et al.  Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. , 2009, Current therapeutic research, clinical and experimental.

[19]  D. Metz,et al.  Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy , 2009, Alimentary pharmacology & therapeutics.

[20]  S. Zeng,et al.  Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? , 2008, World journal of gastroenterology.

[21]  A. Cifuentes,et al.  Liquid separation techniques coupled with mass spectrometry for chiral analysis of pharmaceuticals compounds and their metabolites in biological fluids. , 2006, Journal of pharmaceutical and biomedical analysis.

[22]  N. Yasui-Furukori,et al.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes , 2004, European Journal of Clinical Pharmacology.

[23]  M. Miura,et al.  Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  K. Arimori,et al.  Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. , 2001, Biological and Pharmaceutical Bulletin.

[25]  K. Yasuda,et al.  Pharmacokinetics:Pharmacokinetic Differences Between Lansoprazole Enantiomers in Rats , 1998 .